

12/18/00

JC971 U.S. PTO

09739089-124800

12-20-00
- SIGNATURES MISSING -

A

UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 CFR 1.53(b))	Attorney Docket No.: D/A0489Q	Total Pages: 31
	First Named Inventor or Application Identifier	
	Jaan Noolandi et al.	
	Express Mail Label No.: EE790765644US	

JC971 U.S. PTO
09739089
12/18/00

APPLICATION ELEMENTS See MPEP Chapter 600 concerning utility patent application contents.	ADDRESS TO: Commissioner for Patents Box Patent Application Washington, DC 20231
--	---

<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Specification (incl. claims) (Total Pages: 15)</p> <p>3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) (Total Sheets: 5) <input checked="" type="checkbox"/> Informal <input type="checkbox"/> Formal Use Figure for front page of Publication.</p> <p>4. <input checked="" type="checkbox"/> Oath or Declaration (Total Pages: 2) a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) [Note Box 5 below] <input type="checkbox"/> i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>5. <input type="checkbox"/> Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p>	<p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>7. Nucleotide and/or Amino Acid Sequence Submission (If applicable, all necessary) a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (Identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies</p>
---	---

ACCOMPANYING APPLICATION PARTS
8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
9. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee) <input type="checkbox"/> Power of Attorney
10. <input type="checkbox"/> English Translation Document (if applicable)
11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations
12. <input type="checkbox"/> Preliminary Amendment
13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
14. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired
15. <input type="checkbox"/> Certified Copy of Priority Document(s) (If foreign priority is claimed)
16. <input type="checkbox"/> Other:

17. ☐ If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: /

18. CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Same as prior application <input checked="" type="checkbox"/> Correspondence address below					
NAME	John E. Beck				
ADDRESS	Xerox Corporation, Xerox Square - 20A				
CITY	Rochester	STATE	NY	ZIP CODE	14644
COUNTRY	U.S.A.	TELEPHONE	310-333-3663	FAX	716-423-5240 or 716-423-2750

Attorney Docket No. D/A0489Q

19. ☐ Cancel in this application original claims: of the prior application before calculating the filing fee.
(At least one original independent claim is retained for this filing).

20. ☒ The filing fee is calculated below:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELED BY ABOVE-INDICATED AMENDMENT(S)				
(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
TOTAL CLAIMS (37 CFR 1.16(c))	17 - 20 =	0	x \$ 18	= \$0.00
INDEPENDENT CLAIMS (37 CFR 1.16(b))	2 - 3 =	0	x \$ 80	= \$0.00
MULTIPLE DEPENDENT CLAIMS (IF APPLICABLE) (37 CFR 1.16(d))		ANY - - 0	\$ 270	= \$0.00
BASIC FEE (37 CFR 1.16(a))				\$710.00
TOTAL				= \$ 710.00

21. ☒ The Commissioner is hereby authorized to charge any filing or prosecution fees which may be required, under 37 CFR 1.16, 1.17, and 1.21 (but not 1.18), or to credit any overpayment, to Account No. 24-0025.
An additional copy of this form is enclosed.
22. ☒ This is an authorization under 37 CFR 1.136(a)(3) to treat any concurrent or future reply, requiring a petition for extension of time, as incorporating a petition for the appropriate extension of time.
23. ☐ Amend the specification by inserting before the first line the sentence:
--This application is a ☐ continuation ☐ continuation-in-part ☐ divisional
of Application(s) No(s). , filed .--
24. ☐ A CIP declaration is enclosed.
25. ☐ Power of Attorney
- a. ☐ The power of attorney appears in the original papers of the enclosed prior application.
- b. ☐ Enclosed is a copy of the declaration and power of attorney from the enclosed prior application.
- c. ☐ A new declaration with power of attorney is enclosed.

Attorney Docket No.: D/A0489Q

26. ☐ The following inventors named in the prior application are deleted per 37 CFR 1.53(b)(1), 1.63(d)(2) and 1.33 (b):
27. ☐ This application is adding one or more inventors under 37 CFR 1.48 to a previously executed application, with an enclosed: petition, fee, newly executed declaration from all inventors, and written consent of the assignee.
28. ☐ This application claims the priority benefit of one or more Provisional Application No(s). and the first sentence of this application has been or will be amended to so indicate.
29. ☐ Priority is claimed from
(reinsert all previous priority claims for the entire chain of any prior applications).
30. ☐ **This application is NOT to be published under 35 U.S.C. 112(b). The undersigned attorney or agent hereby certifies that the invention disclosed in this application has not been and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.**
31. ☒ The assignee of this application to be indicated on its publication is Xerox Corporation.
32. ☐ Other paper(s) enclosed:

Respectfully submitted,

Karl L

Kent M. Chen

Signature per 37 CFR 1.33 & 34

Date: 12/15/2000

Registration No. 39,630

Telephone No. 310-333-3663